- Cybin has received conditional listing approval from the New York Stock Exchange
Cybin Inc. (NEO:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”).
“Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.”Doug Drysdale, Cybin’s CEO
Any listing remains subject to the approval of the NYSE American and the satisfaction of all applicable regulatory requirements. No assurance can be given that an application will be approved. The Company plans to maintain its current listing on the NEO Exchange. The Company has reserved the ticker CYBN on the NYSE American.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.